Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Dyslipidemia Market?

Recently, the size of the dyslipidemia market has seen rapid expansion. Projected to rise from a market worth of $16.31 billion in 2024 to $18.08 billion in 2025, it holds a compound annual growth rate (CAGR) of 10.8%. The growth within this historic period can be traced back to factors like increased genetic predisposition, a surge in sedentary lifestyles, a rise in unhealthy dietary habits, a growing aging population, and heightened obesity rates.

What Growth Rate Is Forecasted for the Dyslipidemia Market by 2029?

In the upcoming years, the dyslipidemia market is predicted to experience significant expansion. The market size is projected to reach value of $27.04 billion by 2029, with a 10.6% compound annual growth rate. This predicted growth during the forecasted period is due to factors such as the enhancement of lipid-lowering treatments, increased awareness and screening programs, the increasing incidence of metabolic disorders, heightened healthcare spending, and a growing number of dyslipidemia cases. Key trends within this forecast period include advancements in gene therapy, the development of RNA-based treatments, progress in AI-assisted drug discovery, advancements in tailored medicine, and digital health monitoring innovations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21945&type=smp

Which Key Companies Are Shaping the Future of the Dyslipidemia Market?

Major companies operating in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical

Which Factors Are Driving Demand in the Dyslipidemia Industry?

The dyslipidemia market’s growth is anticipated to be driven by the rising prevalence of obesity. Obesity refers to an unhealthy excess of body fat that can negatively affect a person’s health. Shifts in lifestyle leading to prolonged energy imbalances have contributed to the rising rates of obesity, which in turn promotes gradual weight increase and associated health problems. The correlation between obesity and dyslipidemia rests in the former’s disruption of lipid metabolism, leading to abnormal cholesterol and triglyceride levels that heighten the risk of cardiovascular diseases. For instance, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported in March 2024 that roughly one in eight people globally grapple with obesity. This includes 2.5 billion adults over the age of 18. The figure of overweight children below five years has also hit 37 million. Consequently, the escalating scales of the obese population are fueling the dyslipidemia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21945&type=smp

How Is the Dyslipidemia Market Segmented by Several Divisions?

The dyslipidemia market covered in this report is segmented –

1) By Treatment: Statins, Bile Acid Sequestrants, PCSK9 Inhibitors, Small Interfering RNA (siRNA), Cholesterol Absorption Inhibitors, Fibrates, Niacins, Omega-3 Fatty Acid Derivatives, Other Treatments

2) By Route Of Administration: Oral, Parental

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Store, Online Pharmacies

Subsegmentss:

1) By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin

2) By Bile Acid Sequestrants: Cholestyramine, Colesevelam

3) By PCSK9 Inhibitors: Evolocumab, Alirocumab

4) By Small Interfering RNA (siRNA): Inclisiran

5) By Cholesterol Absorption Inhibitors: Ezetimibe

6) By Fibrates: Fenofibrate, Gemfibrozil

7) By Niacins: Nicotinic Acid

8) By Omega-3 Fatty Acid Derivatives: Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA)

9) By Other Treatments: Herbal Supplements, Combination Therapies

What are the Emerging Market Trends Driving the Growth of the Dyslipidemia Industry?

Leading firms in the dyslipidemia market are prioritizing the development of innovative combination therapies to boost treatment effectiveness, increase patient adherence, and address multiple lipid disorders at once. These cutting-edge combination therapies entail the use of two or more medicinal agents in a singular treatment plan to amplify efficacy, diminish side effects, and simultaneously target various disease pathways. For example, in March 2024, a pharmaceutical corporation based in the US, known as Esperion Therapeutics Inc., announced the FDA approval of NEXLETOL (bempedoic acid) and NEXLIZET (a combined treatment of bempedoic acid and ezetimibe). These innovative non-statin oral drugs are formulated to decrease low-density lipoprotein cholesterol (LDL-C) and minimize the risk of cardiovascular incidents. The new labels authorize the standalone use of NEXLETOL and NEXLIZET or their usage in tandem with statins, a widely used class of cholesterol-lowering medications. This flexibility proves especially advantageous for patients who don’t tolerate statins well or opt for non-statin alternatives.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/dyslipidemia-global-market-report

Which Regions Are Driving Growth in the Dyslipidemia Market?

North America was the largest region in the dyslipidemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyslipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21945

This Report Delivers Insight On:

1. How big is the dyslipidemia market, and how is it changing globally?

2. Who are the major companies in the dyslipidemia market, and how are they performing?

3. What are the key opportunities and risks in the dyslipidemia market right now?

4. Which products or customer segments are growing the most in the dyslipidemia market?

5. What factors are helping or slowing down the growth of the dyslipidemia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model